A new era in the treatment of systemic juvenile idiopathic arthritis

Editorial

Christy Sandborg et al. N Engl J Med. 2012.

. 2012 Dec 20;367(25):2439-40.

doi: 10.1056/NEJMe1212640.

No abstract available

Comment on

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A; PRINTO; PRCSG. De Benedetti F, et al. N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802. N Engl J Med. 2012. PMID: 23252525 Clinical Trial.
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ; PRINTO; PRCSG. Ruperto N, et al. N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099. N Engl J Med. 2012. PMID: 23252526 Clinical Trial.